On Thursday, Merck & Co Inc MRK revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection.
The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (bART) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
DOR/ISL was demonstrated to be non-inferior to bART in open-label trial MK-8591A-051 and non-inferior to BIC/FTC/TAF in double-blind trial MK-8591A-052.
Trial MK-8591A-052 did not meet the superiority criteria, but both trials also met the primary safety objectives.
The company plans to present detailed findings from these trials at a future scientific congress and file the data with regulatory authorities.
In the U.S., doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen [DELSTRIGO; doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF)].
Islatravir (MK-8591), Merck’s investigational drug, is being evaluated in multiple early and late-stage clinical trials in combination with other antiretroviral therapies for the treatment of HIV-1.
In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of DOR/ISL include MK-8591A-053 in people with HIV who had not previously received treatment (treatment-naïve) and MK-8591A-054 evaluating open-label DOR/ISL in individuals who participated in earlier Phase 3 trials of DOR/ISL.
Price Action: MRK stock is up 1.18% at $99.50 at last check Thursday.
Also Read:
Photo: HIV/AIDS ribbon via Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
